Financhill
Sell
29

RLYB Quote, Financials, Valuation and Earnings

Last price:
$0.66
Seasonality move :
-33.39%
Day range:
$0.64 - $0.68
52-week range:
$0.22 - $1.24
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
44.02x
P/B ratio:
0.44x
Volume:
59.1K
Avg. volume:
225K
1-year change:
-37.57%
Market cap:
$28M
Revenue:
$636K
EPS (TTM):
-$0.32

Analysts' Opinion

  • Consensus Rating
    Rallybio Corp. has received a consensus rating of Hold. The company's average rating is a Hold based on 1 Buy rating, 3 Hold ratings, and 0 Sell ratings.
  • Price Target Upside
    According to analysts' consensus price target of $1.00, Rallybio Corp. has an estimated upside of 51.1% from its current price of $0.66.
  • Price Target Downside
    According to analysts, the lowest downside price target is $1.00 representing 100% downside risk from its current price of $0.66.

Fair Value

  • According to the consensus of 4 analysts, Rallybio Corp. has 51.1% upside to fair value with a price target of $1.00 per share.

RLYB vs. S&P 500

  • Over the past 5 trading days, Rallybio Corp. has overperformed the S&P 500 by 1.33% suggesting its relative strength compared to the major market average is strong at this time.

Share Buyback

  • Rallybio Corp. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Rallybio Corp. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Rallybio Corp. reported revenues of $212K.

Earnings Growth

  • Rallybio Corp. has grown year-over-year earnings for 6 quarters straight. In the most recent quarter Rallybio Corp. reported earnings per share of $0.36.
Enterprise value:
-31.2M
EV / Invested capital:
-0.49x
Price / LTM sales:
44.02x
EV / EBIT:
--
EV / Revenue:
-46.24x
PEG ratio (5yr expected):
--
EV / Free cash flow:
0.89x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$555K
Return On Assets:
-21.88%
Net Income Margin (TTM):
-2102.37%
Return On Equity:
-23.97%
Return On Invested Capital:
-23.91%
Operating Margin:
-2464.62%
Trailing 12 Months Fiscal Quarters
Period Ending 2023-09-30 2024-09-30 2025-09-30 2024-09-30 2025-09-30
Income Statement
Revenue -- $598K $674K $299K $212K
Gross Profit -$153K $461K $555K $267K $177K
Operating Income -$74.9M -$70M -$34.9M -$12.1M -$5.2M
EBITDA -$74.8M -$69.9M -$34.7M -$12M -$5.2M
Diluted EPS -$1.80 -$1.59 -$0.32 -$0.26 $0.36
Period Ending 2021-09-30 2022-09-30 2023-09-30 2024-09-30 2025-09-30
Balance Sheet
Current Assets $189.2M $142.4M $132.4M $78.2M $66.6M
Total Assets $193.9M $143.7M $133.2M $79M $67.7M
Current Liabilities $7.3M $11.3M $9.4M $8.2M $4.5M
Total Liabilities $7.4M $11.7M $9.6M $8.2M $4.6M
Total Equity $186.5M $131.9M $123.6M $70.8M $63M
Total Debt -- $428K $211K -- $108K
Trailing 12 Months Fiscal Quarters
Period Ending 2023-09-30 2024-09-30 2025-09-30 2024-09-30 2025-09-30
Cash Flow Statement
Cash Flow Operations -$63.9M -$51.1M -$35M -$13.5M -$6.6M
Cash From Investing -$19.9M $52M $41.8M $22.2M $29.2M
Cash From Financing $51.2M $5.3M $28K -$11K --
Free Cash Flow -$63.9M -$51.1M -$35M -$13.5M -$6.6M
RLYB
Sector
Market Cap
$28M
$28.5M
Price % of 52-Week High
53.37%
51.44%
Dividend Yield
0%
0%
Shareholder Yield
-0.05%
-1.33%
1-Year Price Total Return
-37.57%
-20.32%
Beta (5-Year)
--
0.520
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years

Technicals

8-day SMA
Buy
Level $0.65
200-day SMA
Buy
Level $0.51
Bollinger Bands (100)
Buy
Level 0.52 - 0.64
Chaikin Money Flow
Sell
Level -21.1M
20-day SMA
Buy
Level $0.65
Relative Strength Index (RSI14)
Buy
Level 56.94
ADX Line
Buy
Level 24.01
Williams %R
Neutral
Level -22.2102
50-day SMA
Buy
Level $0.61
MACD (12, 26)
Buy
Level 0.01
25-day Aroon Oscillator
Sell
Level -28
On Balance Volume
Neutral
Level 221.3M

Financial Scores

Sell
Altman Z-Score (Annual)
Level (-4.1551)
Sell
CA Score (Annual)
Level (-1.5334)
--
Beneish M-Score (Annual)
Level (--)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (15.3779)
Buy
Piotroski F Score (Annual)
Level (5)
Sell
Quality Ratio Score
Level (3)
Buy
Fundamental Score
Level (5)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Rallybio Corp. engages in the identification, research and development, and manufacture of clinical biotechnology products and therapies for severe and rare diseases. Its product candidates focus on the areas of fetal and neonatal disorders, hematology, immuno-inflammation, and metabolic disease. The company was founded by Martin W. Mackay, Stephen Uden, and Jeffrey M. Fryer in January 2018 and is headquartered in New Haven, CT.

Stock Forecast FAQ

In the current month, RLYB has received 1 Buy ratings 3 Hold ratings, and 0 Sell ratings. The RLYB average analyst price target in the past 3 months is $1.00.

  • Where Will Rallybio Corp. Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Rallybio Corp. share price will rise to $1.00 per share over the next 12 months.

  • What Do Analysts Say About Rallybio Corp.?

    Analysts are divided on their view about Rallybio Corp. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Rallybio Corp. is a Sell and believe this share price will drop from its current level to $1.00.

  • What Is Rallybio Corp.'s Price Target?

    The price target for Rallybio Corp. over the next 1-year time period is forecast to be $1.00 according to 4 Wall Street analysts, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 3 analysts rate the stock a Hold.

  • Is RLYB A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Rallybio Corp. is a Hold. 3 of 4 analysts rate the stock a Hold at this time.

  • How Can I Buy Shares Of RLYB?

    You can purchase shares of Rallybio Corp. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Rallybio Corp. shares.

  • What Is The Rallybio Corp. Share Price Today?

    Rallybio Corp. was last trading at $0.66 per share. This represents the most recent stock quote for Rallybio Corp.. Yesterday, Rallybio Corp. closed at $0.66 per share.

  • How To Buy Rallybio Corp. Stock Online?

    In order to purchase Rallybio Corp. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Why Did SoFi Stock Drop?
Why Did SoFi Stock Drop?

Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…

Will Robinhood Win AI Investing?
Will Robinhood Win AI Investing?

Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…

Is Amazon an AI Stock?
Is Amazon an AI Stock?

With the market starting to look skittish on pure-play AI…

Stock Ideas

Buy
52
Is NVDA Stock a Buy?

Market Cap: $4.4T
P/E Ratio: 62x

Buy
56
Is AAPL Stock a Buy?

Market Cap: $4.1T
P/E Ratio: 37x

Buy
81
Is GOOG Stock a Buy?

Market Cap: $3.9T
P/E Ratio: 40x

Alerts

Sell
50
TGL alert for Dec 8

Treasure Global, Inc. [TGL] is up 26.93% over the past day.

Buy
56
SMX alert for Dec 8

SMX (Security Matters) Plc [SMX] is down 44.65% over the past day.

Buy
62
PRAX alert for Dec 8

Praxis Precision Medicines, Inc. [PRAX] is up 9.75% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock